Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501555 | 0.96 | L3MBTL1 (0.70) | L3MBTL1HRH3ALDH1A1POLBACACB | |
| SCHEMBL11200681 | 0.91 | L3MBTL1 (0.76) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL28801601 | 0.89 | ALDH1A1 (0.61) | L3MBTL1HRH3ALDH1A1POLBRAB9A | |
| SCHEMBL19717008 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL10399987 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ALDH1A1ACACBRAB9A | |
| SCHEMBL3903106 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL6824717 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3POLBACACBKMT2A | |
| SCHEMBL256037 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL13853398 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBGRM2HTT | |
| SCHEMBL13215733 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ALDH1A1ACACBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025060978-A1 | TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-117916241-A | Spiro compounds | 阿斯利康(瑞典)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3362441-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2017066366-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-3092224-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030139442-A1 | Vasoactive agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1262195-A1 | VASOACTIVE AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-4189495-A | TREATMENT OF NERVOUS AND PSYCHOSOMATIC DISORDERS | SYNTHELABO (FR) | 1980-02-19 | — | — | US | disclosed |
| US-4172143-A | PSYCHOSOMATIC AND PSYCHOLOGICAL DISTURBANCES | SYNTHELABO (FR) | 1979-10-23 | — | — | US | disclosed |
| US-4158060-A | PSYCHOLOGICAL DISORDERS | SYNTHELABO (FR) | 1979-06-12 | — | — | US | disclosed |
| US-4021567-A | FOR PSYCHOSOMATIC AND PSYCHOTIC DISTURBANCES | SYNTHELABO (FR) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139442-A1 | Vasoactive agents | VIPR2, VIPR1, GPR4 | L3MBTL1 4672/4885HRH3 512/4885ALDH1A1 2435/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | L3MBTL1 3149/4885HRH3 202/4885ALDH1A1 3946/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | L3MBTL1 3149/4885HRH3 202/4885ALDH1A1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.